Of note, in the subgroup of BRAF-mutated CRC there was a clinically relevant advantage, although not statistically significant, probably due to the small number of patients (mOS 10.7 vs. 19.0 months, p = 0.54; mPFS 5.5 vs. 7.5 months, p = 0.57, for doublet vs. triplet, respectively) [43]. Here, BRAF is linked to colorectal carcinoma.